Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates in Immuno-Oncology

 Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates in Immuno-Oncology

Takeda Collaborates with LegoChem Biosciences (LCB) to Develop Antibody-Drug Conjugates in Immuno-Oncology

Shots:

  • LCB to receive $7.25M upfront, $404M as regulatory & commercial milestones and royalties on sales of ADCs product. Takeda licenses rights for LCB’s ConjuAll technology including linker and conjugation platform to develop & commercialize targetted immune-oncology therapies for three targets
  • The focus of the collaboration is to utilize LCB’s ADC technology including linker and payload platform in multiple oncology & immune-oncology therapies
  • LCB’s ConjuAll is ADC technology is a platform providing solutions for site-specific conjugation, linker stability and efficient payload release in the development of ADC, antibiotics, anticoagulants and anticancer therapies

Click here to read full press release/ article | Ref: BusinessWire | Image: TheStreet

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post